Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
Pinealon vs. Cagrilintide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both are included in the Relay research library, but their current records answer substantially different questions.
⇄ Different
Biggest Difference
Pinealon is distinguished by a three-amino-acid EDR peptide without an established therapeutic receptor target; its evidence is mostly cell and animal research with limited, methodologically weak human observations; Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
Pinealon is distinguished in the current record by a three-amino-acid EDR peptide without an established therapeutic receptor target; its evidence is mostly cell and animal research with limited, methodologically weak human observations. Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceCagrilintide
Pinealon: Early human evidence. Cagrilintide: Developing human evidence.
Regulatory historyComparable
Pinealon: Not FDA approved. Cagrilintide: Investigational — Phase 3.
Mechanistic breadthComparable
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
Pinealon
- Memory and attention after brain injury
- Age-related cognitive and CNS function
- Oxidative stress and neuronal survival
- Dendritic morphology and synaptic-spine models
Cagrilintide
- Weight management
- Appetite and energy intake
- Obesity with type 2 diabetes
- Visceral and ectopic fat
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
PinealonNot approved
Not FDA approved. No approved indication, product label, consumer dose, injectable route, or official reconstitution and storage procedure was located.
CagrilintideInvestigational
Investigational. No FDA-approved standalone cagrilintide product, consumer dose, reconstitution method, or official storage procedure.
Evidence depthEvidence, not a winner
PinealonLimited human; mostly preclinical
One small mixed-intervention human paper, review-cited older observations, several cell studies, and animal models. No registered Pinealon development program or robust randomized Pinealon-only trial was located.
CagrilintidePhase 2 + Phase 3 pending
One published 706-participant Phase 2 monotherapy trial, a 105-participant thorough-QT study, sponsor-reported Phase 3 component-arm data, and two active dedicated Phase 3 RENEW trials without posted results.
Weight outcomesEvidence, not a winner
PinealonNo direct evidence
No controlled human evidence for weight loss, appetite suppression, or body-composition benefit was located.
CagrilintidePeer-reviewed Phase 2
Phase 2 reported mean reductions of 6.0% to 10.8% across studied cagrilintide arms versus 3.0% placebo at 26 weeks. A sponsor-reported Phase 3 component arm later reported 11.8% versus 2.3% at 68 weeks under an efficacy estimand.
Type 2 diabetesEvidence, not a winner
PinealonNo direct evidence
No controlled human evidence for diabetes treatment or glycemic outcomes was located.
CagrilintidePhase 3 registered
RENEW 2 is studying standalone cagrilintide in adults with overweight or obesity and type 2 diabetes; no results were posted by the cutoff.
Obstructive sleep apnoeaEvidence, not a winner
PinealonNo direct evidence
No controlled human evidence for sleep apnea, sleep quality, or melatonin improvement was located.
CagrilintideNo dedicated evidence
No dedicated completed controlled human obstructive-sleep-apnoea outcome study was located.
Cardiovascular outcomesEvidence, not a winner
PinealonNo outcomes evidence
No controlled cardiovascular-outcomes evidence was located.
CagrilintideQT study only
A 105-participant thorough-QT study found no clinically relevant QTc prolongation at the tested exposure. That narrow result is not a cardiovascular outcomes trial.
Administration and handlingEvidence, not a winner
PinealonOlder oral reports only
Older reports describe oral exposure, but accessible sources do not establish a regulator-approved dose or protocol. No controlled human injectable Pinealon trial was located.
CagrilintideTrial descriptions only
Published and registered studies describe once-weekly subcutaneous administration under protocol-specific escalation. These are trial descriptions, not approved dosing instructions.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Whether any cognitive or cellular signal translates into meaningful human benefit and what short- and long-term human safety looks like.
- Whether the dedicated RENEW Phase 3 trials confirm long-term standalone efficacy and safety in people with and without type 2 diabetes.
Community Intelligence
Emerging patterns, clearly separated from evidence
Pinealon
No community experiences yetBe the first account holder to contribute.
Cagrilintide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.